Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New $1.67 Million Investment in Halozyme Therapeutics, Inc. $HALO

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 25,853 shares of the biopharmaceutical company’s stock, valued at approximately $1,671,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. DLD Asset Management LP grew its stake in Halozyme Therapeutics by 20.0% during the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after acquiring an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after purchasing an additional 25,731 shares in the last quarter. Norges Bank purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $128,201,000. Finally, William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $124,031,000. Institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $51,886,572.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the transaction, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 82,179 shares of company stock valued at $5,687,400. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $79.45 on Friday. The firm has a fifty day moving average price of $69.41 and a 200-day moving average price of $69.42. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The firm has a market capitalization of $9.42 billion, a P/E ratio of 28.58, a P/E/G ratio of 0.33 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 12-month low of $53.33 and a 12-month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter last year, the firm posted $1.11 EPS. The firm’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HALO. Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.